Latest Breaking News On - Kala pharma eysuvis - Page 1 : comparemela.com

2023 is shaping up to be a pivotal year for Aldeyra Therapeutics Inc. (ALDX) as it continues to make significant progress in its pipeline of compounds targeting systemic and retinal immune-mediated diseases.

United statesNovarti xiidraKala pharma eysuvisAllergan restasisAldeyra therapeutics incAldeyra therapeuticsOyster pointRetinitis pigmentosaDry eye diseaseAldeyra therapeutics